Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Delta-like 4 is required for pulmonary vascular arborization and alveolarization in the developing lung
Sheng Xia, Heather L. Menden, Nick Townley, Sherry M. Mabry, Jeffrey Johnston, Michael F. Nyp, Daniel P. Heruth, Thomas Korfhagen, Venkatesh Sampath
Sheng Xia, Heather L. Menden, Nick Townley, Sherry M. Mabry, Jeffrey Johnston, Michael F. Nyp, Daniel P. Heruth, Thomas Korfhagen, Venkatesh Sampath
View: Text | PDF
Research Article Pulmonology Vascular biology

Delta-like 4 is required for pulmonary vascular arborization and alveolarization in the developing lung

  • Text
  • PDF
Abstract

The molecular mechanisms by which endothelial cells (ECs) regulate pulmonary vascularization and contribute to alveolar epithelial cell development during lung morphogenesis remain unknown. We tested the hypothesis that delta-like 4 (DLL4), an EC Notch ligand, is critical for alveolarization by combining lung mapping and functional studies in human tissue and DLL4-haploinsufficient mice (Dll4+/lacz). DLL4 expressed in a PECAM-restricted manner in capillaries, arteries, and the alveolar septum from the canalicular to alveolar stage in mice and humans. Dll4 haploinsufficiency resulted in exuberant, nondirectional vascular patterning at E17.5 and P6, followed by smaller capillaries and fewer intermediate blood vessels at P14. Vascular defects coincided with polarization of lung EC expression toward JAG1-NICD-HES1 signature and decreased tip cell-like (Car4) markers. Dll4+/lacZ mice had impaired terminal bronchiole development at the canalicular stage and impaired alveolarization upon lung maturity. We discovered that alveolar type I cell (Aqp5) markers progressively decreased in Dll4+/lacZ mice after birth. Moreover, in human lung EC, DLL4 deficiency programmed a hypersprouting angiogenic phenotype cell autonomously. In conclusion, DLL4 is expressed from the canalicular to alveolar stage in mice and humans, and Dll4 haploinsufficiency programs dysmorphic microvascularization, impairing alveolarization. Our study reveals an obligate role for DLL4-regulated angiogenesis in distal lung morphogenesis.

Authors

Sheng Xia, Heather L. Menden, Nick Townley, Sherry M. Mabry, Jeffrey Johnston, Michael F. Nyp, Daniel P. Heruth, Thomas Korfhagen, Venkatesh Sampath

×

Figure 7

RNA-Seq identifies lung genes associated with deviant vascular and alveolar development with Dll4 haploinsufficiency.

Options: View larger image (or click on image) Download as PowerPoint
RNA-Seq identifies lung genes associated with deviant vascular and alveo...
(A) The right lungs from Dll4+/+ (n = 6) and Dll4+/lacZ (n = 4) mice were harvested on P6, and RNA extracted was used for RNA-Seq using an Illumina NovaSeq platform. Heatmap of 336 differentially expressed genes between Dll4+/+ (n = 4) and Dll4+/lacZ (n = 4) mouse lungs (P < 0.05). (B) qRT-PCR demonstrates Aqp5, Pdpn, Hopx, Esr2, Klf2, Spc, and Pdgfrα expression in Dll4+/+ and Dll4+/lacZ mouse lungs at P4, P14, and P28. (C) AQP5 (green) and SPC (red) IF staining with DAPI (blue) in Dll4+/+ and Dll4+/lacZ mouse lungs at P14, with quantification shown for percentage of SPC+ cells of the total DAPI-stained cells (D), n = 6 in each group and P < 0.005. (E) Mouse lungs were harvested from Dll4+/+ and Dll4+/lacZ mice at P14 and P28. Lung homogenates were used to quantify SPC and PDGFRA by immunoblotting, with densitometry shown graphically (F), n = 5 mice per group; P < 0.01. (G) PDGFRA (brown) IHC staining with Harris staining (blue) on P8 and P14 Dll4+/+ and Dll4+/lacZ mouse lung sections, with quantification shown for percentage of PDGFRA+ cells in total Harris-stained cells (H), n = 6 in each group, *P < 0.05, **P < 0.01, and ***P < 0.001. Scale bar: 20 μm. Data are shown as mean ± SD. (B, F, and H) Gaussian distribution used 1-way ANOVA with Tukey’s test. (D) Gaussian distribution with 1 comparison used 2-tailed t test with Welch’s correction.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts